Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.

Trial Profile

Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
    • 15 Dec 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Feb 2016, as reported by ClinicalTrials.gov.
    • 30 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top